Core Insights - Compugen Ltd. is set to present a pooled analysis of data from three Phase 1 trials of COM701 for treating heavily pretreated platinum-resistant ovarian cancer patients at ESMO 2025 in Berlin [1][2] Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes AI/ML for predictive computational drug target discovery [2] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [2] - Compugen's pipeline includes early-stage immuno-oncology programs aimed at activating the immune system against cancer [2] - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [2]

Company Overview - Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in predictive computational drug target discovery using AI/ML technologies [3] - The company is headquartered in Israel and has an office in San Francisco, CA, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3] Upcoming Financial Results - Compugen will release its second quarter 2025 financial results on August 6, 2025, before U.S. financial markets open [1] - A conference call and webcast will be held at 8:30 AM ET to review the results and provide a corporate update [1] Product Pipeline - Compugen has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3] Research Programs - The company has a therapeutic pipeline focused on early-stage immuno-oncology programs aimed at activating the immune system against cancer through new mechanisms [3]

Core Insights - Compugen Ltd. has initiated the first patient dosing in a global randomized sub-trial of its adaptive platform trial, MAIA-ovarian, focusing on the maintenance therapy with COM701 for relapsed platinum-sensitive ovarian cancer [1][2][5] Group 1: Trial Details - MAIA-ovarian is designed to evaluate the safety and efficacy of COM701 as maintenance monotherapy or in combination therapy for patients with relapsed platinum-sensitive ovarian cancer [3][5] - Sub-trial 1 is a double-blind, randomized placebo-controlled trial involving 60 patients, randomized in a 2:1 ratio to receive COM701 or placebo [3][5] - An interim analysis of sub-trial 1 is scheduled for the second half of 2026, which may inform a registration path for COM701 monotherapy [2][5] Group 2: Clinical Rationale and Expectations - The trial is supported by strong biological rationale, with high PVRIG pathway expression levels observed in ovarian cancer, indicating a significant unmet medical need [2][3] - Historical data suggests a benchmark for progression-free survival of around six months, with a clinically meaningful improvement of three months over placebo anticipated [2][5] - COM701 has shown durable responses in previous clinical data, including a response duration of over 18 months in a patient treated as a single agent [2][5] Group 3: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company utilizing AI/ML for predictive computational target discovery, focusing on cancer immunotherapies [4][6] - The company has two proprietary product candidates in Phase 1 development: COM701 and COM902, targeting different pathways in cancer treatment [4][6] - Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [6]

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that utilizes AI/ML driven predictive computational research to enhance understanding of complex cancer biology [1][2]. Group 1: Conference Presentations - Compugen will present at the 2025 Annual Congress of the European Association for Cancer Research in Lisbon, Portugal, from June 16-19, with a poster titled "Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes" [2]. - Another presentation will occur at the International Society for Computational Biology and European Conference on Computational Biology in Liverpool, UK, from July 20-24, featuring a poster titled "Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms" [2]. Group 2: Company Overview - Compugen employs a predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for cancer immunotherapy development [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3]. - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3].

Core Viewpoint - Compugen Ltd. is set to release its first quarter 2025 financial results on May 19, 2025, and will host a conference call for a corporate update [1]. Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes its predictive computational discovery platform, Unigen™, to identify new drug targets and biological pathways [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3]. - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3]. - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3].

Core Viewpoint - BeiGene has decided to terminate the clinical development of its TIGIT inhibitor, ociperlimab, after an independent data monitoring committee recommended stopping the ongoing Phase III AdvanTIG-302 trial due to the likelihood of not meeting the primary endpoint of overall survival [1][2]. Group 1: Company Actions - BeiGene has invested a total of 2.09 billion RMB (approximately 20.9 million) in the ociperlimab project as of the first half of 2024 [1][2]. - The decision to terminate the trial was made after careful consideration of the efficacy and safety data, with no new safety signals identified [2]. - Following the termination of the trial, BeiGene will focus its resources on more promising candidates with clinical differentiation [2]. Group 2: Collaboration and Financials - In December 2021, BeiGene entered into an option agreement with Novartis, granting Novartis exclusive rights to develop, manufacture, and commercialize ociperlimab, for which BeiGene received a $300 million upfront payment [3]. - In July 2024, BeiGene and Novartis signed a termination agreement, allowing BeiGene to regain all global rights to ociperlimab [3]. - As of the end of 2023, BeiGene reported collaboration revenue related to the ociperlimab agreement of $192 million (approximately 1.41 billion RMB), which is expected to decrease to $18.26 million (approximately 134 million RMB) by the end of 2024 [4]. Group 3: Industry Context - The TIGIT pathway has been a popular target in cancer treatment development, with multiple pharmaceutical companies, including Roche, Bristol-Myers Squibb, and Merck, also halting their TIGIT antibody research due to unsatisfactory results [5][6]. - Despite the setbacks, some companies, such as AstraZeneca and GSK, continue to pursue TIGIT-related therapies, with ongoing clinical trials for their respective candidates [6].

Company Overview - Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in computational target discovery [3] - The company utilizes its predictive computational discovery platform, UnigenTM, to identify new drug targets and biological pathways for cancer immunotherapies [3] - Compugen has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] Upcoming Events - Compugen will participate in several virtual investor conferences in April 2025, including: - H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference on April 2, 2025, with a fireside chat at 9:30 am ET [1] - 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, with a fireside chat at 8:00 am ET [2] - Stifel's 2025 Virtual Targeted Oncology Forum on April 9, 2025, with a fireside chat at 12:00 pm ET [2] - Live webcasts of the fireside chats will be available on Compugen's Investor Relations website, with replays accessible after the events [2] Product Development - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a license agreement [3] - GS-0321 (previously COM503), an anti-IL-18 binding protein antibody, is in Phase 1 development and licensed to Gilead [3] - The company has a pipeline of early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3]